Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the XEN63 glaucoma gel stent implanted using two different surgical methods ab interno inside the eye and ab externo outside the eye. This study focuses on patients with glaucoma who have not responded well to medical treatments or conventional surgeries. The trial aims to compare outcomes such as adverse events and intraocular pressure control over 12 months. Participants will be randomly assigned to receive the XEN63 gel stent implanted via either the ab interno or ab externo approach on Day 1. About 130 adults aged 45 years or older with glaucoma will join this study. After implantation, participants will be followed for up to 12 months with regular hospital or clinic visits to monitor safety and effectiveness. During the study, participants will undergo medical assessments and eye exams to measure intraocular pressure and check for any adverse events. The main outcomes include the percentage of participants achieving a 20% or greater reduction in intraocular pressure on the same or fewer medications after 12 months. Secondary measures include changes in daily intraocular pressure and medication use. The study will be completed by November 2028.
Actively Recruiting
Researchers are evaluating a preservative-free formulation of Bimatoprost ophthalmic solution 0.01% YSBP compared to Lumigan49 bimatoprost ophthalmic solution 0.01% in adults with primary open-angle glaucoma POAG or ocular hypertension OH. The purpose is to establish whether YSBP is not less effective than Lumigan49 in lowering eye pressure in these patients. Participants will be randomly assigned to receive either YSBP or Lumigan49 eye drops. Both treatments contain bimatoprost 0.01%, and the study is designed as a double-blind, active-controlled, parallel-group trial. The treatment period lasts 12 weeks, during which participants will use the assigned eye drops as directed. During the study, participants will undergo regular eye pressure measurements, including the primary outcome of intra-ocular pressure at Week 12. Visual acuity and safety assessments will also be performed. Women of childbearing potential must use effective contraception. The study includes screening, a washout period for prior eye medications, treatment visits, and safety monitoring through the completion date in late 2027.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NEXAGON4 lufepirsen ophthalmic gel in people with persistent corneal epithelial defects PCED, a condition where the corneal surface does not heal properly. This randomized, double-masked, vehicle-controlled study aims to understand how well NEXAGON works in treating PCED and its durability after treatment. This Phase 2 trial is sponsored by Glaukos Corporation and is conducted at multiple centers. Participants will be randomly assigned to receive one of three treatments applied topically to the eye once a week for 4 to 8 weeks a high dose of lufepirsen, a low dose of lufepirsen available only at EU sites, or a vehicle gel without the active drug. After the treatment period, a 4-week follow-up will monitor the condition. If the corneal defect does not heal or the healing is not maintained for 28 days, participants may enter an open-label treatment phase with NEXAGON for an additional 8 weeks. During the study, participants will undergo screening to confirm eligibility, receive weekly treatment applications, and be monitored for safety and healing progress. Researchers will assess corneal re-epithelialization and its durability as the main outcome. The total study participation includes the screening, up to 8 weeks of treatment, 4 weeks of follow-up, and possibly an 8-week open-label extension. Safety, efficacy, and healing durability will be closely observed throughout these periods.
Actively Recruiting
Researchers are evaluating the bioequivalence of two eye drop treatments, Bimatoprost 0.01% ophthalmic solution by Amneal EU and LUMIGAN4 bimatoprost ophthalmic solution 0.01% by Allergan, in adults with chronic open-angle glaucoma or ocular hypertension affecting both eyes. This randomized, double-blind, parallel-group study aims to compare these treatments by measuring their effects on intraocular pressure IOP as the primary clinical endpoint. Participants will be randomly assigned to receive either the test or reference bimatoprost eye drops, instilling one drop in both eyes every evening around 1000 pm for 42 days. The study includes multiple doses over this period, with evaluations occurring at baseline, two weeks, and six weeks. The test and reference products are both ophthalmic solutions containing the same concentration of bimatoprost. Throughout the study, participants will have clinical assessments to monitor safety and efficacy, including IOP measurements at specific times 0000, 0400, and 0800 hours on days 14 and 42. Safety monitoring for adverse events will continue during the six-week treatment period. The main outcome is the mean difference in IOP between the treatment groups, helping to determine if the test product is equivalent to the reference product in controlling eye pressure.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the VisiPlate Aqueous Shunt, a tiny implant designed to lower eye pressure in patients with refractory open-angle glaucoma. This condition includes open angle, pseudoexfoliative, or pigmentary glaucoma where other medical and surgical treatments have not succeeded. The trial is prospective, multicenter, single-arm, and open-label, focusing on treatment for adults aged 45 and older. Participants will receive the VisiPlate Glaucoma Implant, a device placed in the eye to help reduce intraocular pressure between 20 and 40 mmHg. The study will follow participants for at least 12 months to observe changes in eye pressure and the proportion of subjects achieving a 20% or greater reduction in mean diurnal intraocular pressure. Throughout the study, participants will undergo regular evaluations of their eye pressure and visual function, including measuring visual field changes and assessing the implanted device. The main outcome is the reduction in eye pressure at 12 months, with safety monitored by observing any eye infections, inflammation, or other complications. The total duration of participation aligns with the 12-month follow-up period to assess the implants effectiveness and safety.